Low-grade prostate cancer diverges early from high grade and metastatic disease

Understanding the developmental relationship between indolent and aggressive tumors is central to understanding disease progression and making treatment decisions. For example, most men diagnosed with prostate cancer have clinically indolent disease and die from other causes. Overtreatment of prostate cancer remains a concern. Here we use laser microdissection followed by exome sequencing of low‐ and high‐grade prostate cancer foci from four subjects, and metastatic disease from two of those subjects, to evaluate the molecular relationship of coincident cancer foci. Seventy of 79 (87%) high‐confidence somatic mutations in low‐grade disease were private to low‐grade foci. In contrast, high‐grade foci and metastases harbored many of the same mutations. In cases in which there was a metastatic focus, 15 of 80 (19%) high‐confidence somatic mutations in high‐grade foci were private. Seven of the 80 (9%) were shared with low‐grade foci and 65 (82%) were shared with metastatic foci. Notably, mutations in cancer‐associated genes and the p53 signaling pathway were found exclusively in high‐grade foci and metastases. The pattern of mutations is consistent with early divergence between low‐ and high‐grade foci and late divergence between high‐grade foci and metastases. These data provide insights into the development of high‐grade and metastatic prostate cancer.

[1]  Sarah H. Johnson,et al.  Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. , 2013, Cancer research.

[2]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[3]  J. Lindberg,et al.  Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. , 2013, European urology.

[4]  G. Bubley,et al.  Clonal progression of prostate cancers from Gleason grade 3 to grade 4. , 2013, Cancer research.

[5]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[6]  M. Cooperberg,et al.  Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[8]  Janet E Cowan,et al.  Do Adenocarcinomas of the Prostate With Gleason Score (GS)⩽6 Have the Potential to Metastasize to Lymph Nodes? , 2012, The American journal of surgical pathology.

[9]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.

[10]  D. Berney,et al.  High‐resolution genome‐wide copy‐number analysis suggests a monoclonal origin of multifocal prostate cancer , 2012, Genes, chromosomes & cancer.

[11]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[12]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[13]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[14]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[15]  Stephen J. Salipante,et al.  Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.

[16]  Misop Han,et al.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.

[17]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[18]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[19]  K. Pienta,et al.  Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. , 2011, Genome research.

[20]  D. Altshuler,et al.  A map of human genome variation from population-scale sequencing , 2010, Nature.

[21]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[22]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[23]  Matthias Meyer,et al.  Illumina sequencing library preparation for highly multiplexed target capture and sequencing. , 2010, Cold Spring Harbor protocols.

[24]  Philip L. F. Johnson,et al.  Targeted Investigation of the Neandertal Genome by Array-Based Sequence Capture , 2010, Science.

[25]  A. D'Amico,et al.  NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[26]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[27]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[28]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[29]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[30]  R. Shah,et al.  Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. , 2007, Cancer research.

[31]  Anthony D'Amico,et al.  Prostate cancer. Clinical practice guidelines in oncology. , 2007, Journal of the National Comprehensive Cancer Network : JNCCN.

[32]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[33]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[34]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.